The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands

Mohamed N M T Al Khayat*, Job F H Eijsink, Maarten J Postma, Jan C Wilschut, Marinus van Hulst

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
36 Downloads (Pure)

Abstract

OBJECTIVE: We aimed to assess the cost-effectiveness of hepatitis C virus (HCV) screening strategies among recently arrived migrants in the Netherlands.

METHODS: A Markov model was used to estimate the health effects and costs of HCV screening from the healthcare perspective. A cohort of 50,000 recently arrived migrants was used. In this cohort, three HCV screening strategies were evaluated: (i) no screening, (ii) screening of migrants from HCV-endemic countries and (iii) screening of all migrants.

RESULTS: Strategy (ii) screening of migrants from HCV-endemic countries compared to strategy (i) no screening, yielded an incremental cost-effectiveness ratio (ICER) of €971 per quality-adjusted life-years (QALYs) gained. Strategy (iii) screening of all migrants compared with strategy (ii) screening of migrants from HCV-endemic countries yielded an ICER of €1005 per QALY gained. The budget impact of strategy (ii) screening of migrants from HCV-endemic countries and strategy (iii) screening of all migrants was €13,752,039 and €20,786,683, respectively.

CONCLUSION: HCV screening is cost-effective. However, the budget impact may have a strong influence on decision making.

Original languageEnglish
Article number6091
Pages (from-to)1-13
Number of pages13
JournalInternational Journal of Environmental Research and Public Health
Volume17
Issue number17
DOIs
Publication statusPublished - Sep-2020

Keywords

  • Cost-Benefit Analysis
  • Hepacivirus
  • Hepatitis C/diagnosis
  • Humans
  • Markov Chains
  • Mass Screening
  • Netherlands
  • Quality-Adjusted Life Years
  • Transients and Migrants

Cite this